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PEGyAMPH is a brain-sparing modified
amphetamine that is a cardioneutral anti-
obesity drug. Unlike amphetamines,
which act in the brain to increase satiety
and locomotion, PEGyAMPH couples
thermogenesis to heat dissipation,
activating a whole-body energy sink by
simultaneously promoting vasodilation
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https://doi.org/10.1016/j.cmet.2020.04.013SUMMARYAnti-obesity drugs in the amphetamine (AMPH) class act in the brain to reduce appetite and increase loco-
motion. They are also characterized by adverse cardiovascular effects with origin that, despite absence of
any in vivo evidence, is attributed to a direct sympathomimetic action in the heart. Here, we show that the
cardiac side effects of AMPH originate from the brain and can be circumvented by PEGylation (PEGyAMPH)
to exclude its central action. PEGyAMPH does not enter the brain and facilitates SNS activity via theb2-adre-
noceptor, protecting mice against obesity by increasing lipolysis and thermogenesis, coupled to higher heat
dissipation, which acts as an energy sink to increase energy expenditure without altering food intake or lo-
comotor activity. Thus, we provide proof-of-principle for a novel class of exclusively peripheral anti-obesity
sympathofacilitators that are devoid of any cardiovascular and brain-related side effects.Context and Significance
Amphetamine-like drugs have anti-obesity action, which is associatedwith increased satiety and locomotion, but are known
to cause cardiac side effects. Mahú et al. found that these side effects originate centrally and created a brain-sparing drug
by chemically modifying amphetamine through PEGylation (PEGyAMPH). This new molecule promotes weight loss via mo-
lecular and physiological mechanisms, which are unrelated to those of centrally acting amphetamines. PEGyAMPH couples
heat production to its simultaneous dissipation to act as a whole-body energy sink. It acts via b2-adrenoceptors to promote
vasodilation, while facilitating the activity of fat burning peripheral neurons. These findings provide proof-of principle for the
development of anti-obesity drugs that act peripherally, while circumventing the brain.
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Anti-obesity drugs in the amphetamine (AMPH) class, such as
FDA-approved phentermine, are highly efficacious therapeutic
compounds approved for common obesity (Cooke and Bloom,
2006; Melnikova and Wages, 2006). The potent anti-obesity ac-
tion of this class of drugs is reportedly mediated by a stimulant
action in the brain that suppresses appetite and promotes hyper-
kinesia (Cooke and Bloom, 2006; Heal et al., 2013; Melnikova
and Wages, 2006). Although their anti-obesity effects are unpar-
alleled, these drugs are not only addictive, but also drive cardio-
vascular side effects, such as tachycardia and hypertension. It is
so far unclear whether these side effects originate peripherally or
centrally in the brain. Central action is a viable possibility, as the
brain robustly controls heart rate and vascular capacitance in
response to multiple internal and external stimuli (Malpas,
2010). However, despite the lack of direct experimental evi-
dence, the peripheral model has prevailed, wholly on empirical
grounds. Specifically, no direct evidence exists regarding the
in vivo origin of any cardiovascular side effects or whether a car-
dioneutral anti-obesity effect could result if AMPH is excluded
from the brain.
All AMPHs are coined as indirect sympathomimetics because
they block monoamine transporters, thus increasing catechol-
amine availability (Cooke and Bloom, 2006; Heal et al., 2013;
Melnikova and Wages, 2006). Recent evidence demonstrates
that the genetic loss of function of norepinephrine (NE) trans-
porter (Slc6a2) outside the brain promotes weight loss, without
any changes in food intake (FI) or locomotor activity (LA) (Pirz-
galska et al., 2017). As such, we hypothesized that preventing
access of sympathomimetic drugs to the brain would be suffi-
cient to promote weight loss, independent of behavior. To test
this hypothesis, we chemically modified AMPH by PEGylation
to increase its hydrodynamic radius and prevent its access to
the brain (Pereira et al., 2017). PEGyAMPH does not cross
the blood-brain barrier (BBB), yet retains the capacity to facili-
tate activation of sympathetic neurons and to increase periph-
eral NE availability in adipose tissues. Orthogonal to our initial
hypothesis, we uncovered that this effect is mediated by
engagement with the b2-adrenoceptor (ADRB2), a well-known
mediator of vasodilation and smooth muscle relaxation (Chrus-
cinski et al., 1999; Ernande et al., 2016). We found that unlike
AMPH, PEGyAMPH does not block Slc6a2 and it is devoid of
cardiovascular effects, which re-emerge if directly delivered
to the brain. PEGyAMPH has an anti-obesity size effect similar
to that of AMPH, yet without suppression of FI or increased LA.
Its anti-obesity effect is attributable to elevated lipolysis and
lipid utilization, and increased thermogenesis coupled with
higher heat dissipation, which combinedly contribute to sink
energy while overriding caloric intake (Jung et al., 1979; Kasza
et al., 2019; Schwartz et al., 1983; Wang, 1924; Warner
et al., 2013).
RESULTS
The Anti-obesity Effect of Amphetamines Requires an
Intact SNS
Despite being classified as sympathomimetic, to the best of our
knowledge, there are no literature reports on the ability of AMPHto directly activate sympathetic neurons. To bridge this literature
gap, we utilized both electrophysiology and intracellular calcium
([Ca2+]i) imaging to probe the effects of AMPH on the excitability
of neurons isolated from superior cervical ganglia (SCG). By
recording firing patterns of sympathetic neurons from C57BL/6
mice through whole-cell patch-clamp under current-clamp
mode (Figures 1A and 1B), we observed that AMPH significantly
increases the maximum firing frequency (Figure 1C, left panel),
without changing resting membrane potential (Figure 1C, right
panel). In parallel, we also used dissociated cultures of TH-cre;-
CAG-LSL-GCaMP3 (GCaMP3+) reporter mice to perform [Ca2+]i
imaging. Local application of acetylcholine (ACh), a physiologic
SNS activator, leads to an [Ca2+]i increase in GCaMP3
+ neurons,
which then results in a significantly higher response upon treat-
ment with AMPH (Figures 1D–1F). Hence, these results confirm
that AMPH treatment increases the intrinsic excitability of sym-
pathetic neurons.
Next, to investigate whether the increase in SNS tone is
required for the anti-obesity effect of AMPH, we subjected
LSL-DTR (control) and sympathectomized TH-cre; LSL-DTR
mice (Symp; Pereira et al., 2017; Figure S1A) to an obesogenic
high-fat diet (HFD) plus treatment with AMPH (120 mmol/kg of
body weight [BW]) or with phosphate-buffered saline (PBS) as
control, via daily intraperitoneal (i.p.) injections, for a total of
6 weeks. As expected, AMPH treatment protects control mice
from diet-induced obesity (DIO) (Figures 1G and S1B), and, as
previously reported (Pereira et al., 2017), Symp mice become
extremely prone to DIO (Figure 1G). Surprisingly, both cohorts
of Symp mice had similar rate of BW-gain upon HFD exposure,
regardless of treatment, which led to an approximately 40% in-
crease after just 6 weeks (Figures 1G and S1B). This happened
independent of behavioral changes (Figures 1H–1J), as, upon
treatment, both control and Symp groups showed great reduc-
tion in FI (Figure 1H) and increase in LA (Figures 1I and 1J).
Thus, we theorized that underlying this phenotype was the
reduction in sympathetic output, which would lead to a depres-
sion of adrenergic-stimulated lipolysis (Caron et al., 2018; Per-
eira et al., 2017; Schwartz et al., 1983). To assess this, we quan-
tified both the NE content of the inguinal white adipose tissue
(iWAT) and the plasma levels of lipolysis markers after AMPH
treatment. Indeed, Symp mice had a significantly dampened
SNS response to AMPH (Figure 1K), which was accompanied
by a reduction in stimulated lipolysis (Figure S1C). Combined,
these results strongly support that the sympathomimetic activity
of AMPH is required for its protection against weight gain. More
importantly, the reduced FI and increased LA observed upon
AMPH treatment are ineffective at reducing the rate of BW-
gain in the absence of an intact SNS (Bray, 1991; Spraul
et al., 1993).
PEGylation of AMPH Prevents Its Access to the Brain
and Its Behavioral Effects
The BBB is generally impervious to large molecules; thus, we re-
sorted to chemical modification of AMPH by PEGylation (Pereira
et al., 2017, see STAR Methods) to increase the hydrodynamic
radius size here, named as PEGyAMPH (Figure 2A). To assess
the success of this modification, we injected adult C57BL/6
mice with AMPH or PEGyAMPH (120 mmol/kg of BW for both
drugs, i.p.) and collected brains after 30 min and 2 h. TheCell Metabolism 31, 1120–1135, June 2, 2020 1121
Figure 1. Amphetamine (AMPH) Facilitates SNS Activation, Which Is Required for the Anti-obesity Effect, Independently of Hypophagia and
Hyperkinesia
(A) Cultured GCaMP3+ SCG neurons immuno-labeled for tyrosine hydroxylase (TH).
(B) Representative traces of changes in membrane potential and action potential (AP) evoked under current-clamp mode in Vehicle and AMPH-treated SCG
neurons.
(C) Maximum AP firing frequency and resting membrane potential.
(D) Sequence of representative pseudocolor images showing calcium levels ([Ca2+]i) in GCaMP3
+ neurons after stimulation with ACh. Changes in fluorescence
(DF) are expressed as DF/F0 = [(Fpost  Frest)/Frest] and represented in pseudocolor scale.
(legend continued on next page)
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ion cyclotron resonance (FT-ICR) mass spectrometry to detect
the presence of either molecule. Given its high resolution, one
can identify the compound with errors lower than 1.5 ppm, and
only in the group treated with AMPH was the drug detectable
(Figure 2B). Additionally, we processed brain tissues from both
time points by liquid chromatography with mass spectrometry
(LCMS) detection (quantitative). Possibly due to minimal pene-
tration in areas where the BBB is not complete, we found a negli-
gible quantity of PEGyAMPH 30 min after i.p. administration,
which then became completely undetectable 2 h post-injection
(Figure 2C). To consolidate our results, we then probed behav-
ioral alterations in free-moving mice after i.p. administration of
both drugs. According to our previous results, AMPH treatment
consistently suppresses FI (Figure 2D) and increases LA (Figures
2E and 2F). Importantly, no changes in behavior were observed
in PEGyAMPH-injected mice relative to those of the control ani-
mals (Figures 2D–2F).Hence, we could conclude that PEGylation
of AMPH (PEGyAMPH) successfully restrains its brain action.PEGyAMPH Facilitates SNS Activation, via ADRB2
Signaling
To investigate PEGyAMPH’s biologic activity, we again treated
SCG neurons with either AMPH or PEGyAMPH and recorded
the firing patterns, using whole-cell patch-clamp (Figures 3A,
3B, and S3A–S3C). The maximum firing frequency of PE-
GyAMPH-treated SNS neurons increased relative to that of con-
trols (Figure 3B), like AMPH, without changes in resting mem-
brane potential (Figure S3A). Moreover, we found a significant
increase in the AP firing threshold and in the D depolarization
for AP firing that was only detected between Vehicle and PE-
GyAMPH (Figures S3B and S3C). The ACh-induced [Ca2+]i
response of GCaMP3+ neurons incubated with PEGyAMPH
was similar to that observed in AMPH-treated neurons (Figures
3C–3E). Thus, our results confirm that PEGyAMPH, like AMPH,
increases the intrinsic excitability of sympathetic neurons. To
further assess whether PEGyAMPH also had the capacity to
elevate the SNS tone in vivo, we conducted a dose response
curve in C57BL/6 mice, and found the NE content of metabolic
tissues to be increased in a dose-dependent manner (Figure 3E,
left: iWAT; right: Liver).
We then probed the effects of PEGylation on the drug’s phar-
macologic properties. AMPH accumulates in the brain and has a
circulating half-life of 20 min in mice (Riffee et al., 1978). Our
pharmacokinetic analysis revealed that PEGyAMPH has shorter
plasma half-life (Figure S2A, 0.2 h versus 0.36 h, respectively), it
is more quickly metabolized in the liver (Figure S2B), and, as ex-
pected, is much less excreted via urine (Figure 2C) (Harris and
Chess, 2003). Additionally, to explore the functional properties(E) Representative ACh-induced [Ca2+]i response tracings.
(F) Amplitude of ACh-induced [Ca2+]i transients (n = 8; statistics done using one-
(G) Change in body weight (DBW) of control and regionally Sympmice during HFD
10–13. Statistics done using two-way ANOVA).
(H) Daily food intake during HFD exposure and respective treatment.
(I) Representative tracking of the LA.
(J) Total distance traveled in 10 min.
(K) NE content in iWAT. (n = 6–12; statistics done using unpaired Student’s t tes
*,d,#p < 0.05; *PBS versus AMPH; dcontrol+PBS versus Symp+PBS; #control+AMof PEGyAMPH, we started by testing its capacity to bind
Slc6a2 in vitro, as this is reported to be a major target of
AMPH (Heal et al., 2013) and found a marked difference in the
binding to this target: while AMPH displaces 80% of the radio-
ligand at 50 mM, its PEGylated counterpart shows no activity
(Figure S2D). This suggests that although the sympathomimetic
effects are similar, the pharmacology of the two drugs differs. As
such, we then evaluated the effect of replacing the NH3
+ of
AMPH by an amide group, in other potential interactions of PE-
GyAMPH with adrenoceptors for which there are available X-
ray structures. For this, we conducted docking calculations for
both AMPH and PEGyAMPH with either b1-adrenoceptor
(ADRB1) or ADRB2 (Figures 3F and S3D, respectively). Accord-
ing to our calculations, the NH3
+ group of AMPH is engaged in a
hydrogen bond with the side chain of Asp256 of the ADRB2 (Fig-
ure 3F, left panel, see STARMethods for details). In addition, the
methyl group of the drug is involved in a CH-p interaction with
Phe336 of the receptor, and its aromatic ring establishes hydro-
phobic contacts with several residues of ADRB2. The complex
between PEGyAMPH and ADRB2 is stabilized by several
hydrogen bonds. Of note, a prevalent one is formed between
the NH group of PEGyAMPH and the side chain of Asp256 of
the receptor, while an additional one involves the carbonyl group
of the PEGylated compound and Tyr423 of ADBR2. Further-
more, the PEG chain is also involved in two other hydrogen
bonds with the side chains of His236 and Lys240 of the
ADRB2 (Figure 3F, right panel). As such, the replacement of
the NH3
+ by an amide group does not significantly disturb the in-
teractions with the adrenoceptors tested, which is aligned with
PEGyAMPH’s ability to modulate SNS tone to metabolic tissues
(Figures 3E, S3E, and S3F).
To experimentally probe the effect of specific engagement of
the ADRB2 by PEGyAMPH on its sympathofacilitator properties,
we repeated the ACh-induced [Ca2+]I response assays and
found that butoxamine (BUT), a selective ADRB2 antagonist (Ga-
banyi et al., 2016), blocked PEGyAMPH’s capacity to amplify
neuronal activation (Figure 3G). Hence, PEGylation of AMPH
changed its pharmacology, but it did not reduce the sympatho-
facilitator activity, which relies on ADRB2 engagement.PEGyAMPH Does Not Affect Cardiovascular Function in
Mice, Unless It Is Centrally Delivered
The anti-obesity effects of AMPH-like compounds are proposed
to be driven by their modulation of behavior, yet these drugs are
coined sympathomimetics (Heal et al., 2013) in reference to their
well-known cardiovascular side effects. Yet, it is so far unclear
whether these originate peripherally by direct activation of the
SNS by AMPH or centrally by a brain-dependent action (Heal
et al., 2013). Surprisingly, we found that the peripherally actingway ANOVA, followed by Bonferroni correction).
exposure plus treatment with PBS or AMPH (120 mmol/kg of BW, daily i.p. - n =
t, with Holm-Sidak correction method).
PH versus Symp+AMPH. Data presented as mean ± SEM. See also Figure S1.
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Figure 2. Pegylated Amphetamine (PEGyAMPH) Does Not Enter the Brain and Does Not Induce Hypophagia or Hyperkinesia
(A) Representative scheme of the AMPH’s PEGylation method to produce PEGyAMPH.
(B) Representative FT-ICR mass spectra of brain extracts from C57BL/6 mice 30 min post-injection with AMPH or PEGyAMPH (120 mmol/kg of BW, i.p.).
(C) Brain levels of AMPH and PEGyAMPH.
(D) 24 h FI post-injection with PBS, AMPH, or PEGyAMPH (normal diet).
(E) Total distance traveled in 15 min.
(F) Representative tracking of LA (n = 4–10; statistics done using unpaired Student’s t test, with Holm-Sidak correction method).
*,#p < 0.05; *PBS versus PEGyAMPH; #PBS versus AMPH. Data presented as mean ± SEM. See also Figure S2.
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OPEN ACCESS Articledrug did not cause elevation of blood pressure (Figures 4A and
4B) or heart rate (Figures 4C and S4A) upon i.p. administration.
Concomitantly, we also detected less accumulation of the drug
(Figure S4B) and of NE in the hearts (Figure S4C) of animals
treated with PEGyAMPH compared with those treated with
AMPH. Hence, a central action seems to be a viable possibility
(Malpas, 2010). To test this, weprobed the effect of central admin-
istration of both drugs by intracerebroventricular (i.c.v.) injection
(bolus of 60 nmol). PEGyAMPHhad equivalent anorexigenic effect
(Figure 4E) and capacity to increase LA (Figures 4F and 4G) to that
of AMPH. Importantly,we confirmed that i.c.v. injectionswere suf-
ficient to induce excitatory effects on the cardiorespiratory system
(Figures 4D and S4D). Combined, our results suggest that the
well-described cardiovascular stress induced by sympathomi-
metic drugs is driven by their central action on the brain.1124 Cell Metabolism 31, 1120–1135, June 2, 2020PEGyAMPHProtectsMice fromObesity by Elevating EE,
without Affecting Feeding Behavior or Locomotion
Recent evidence from our group and others (Camell et al., 2017;
Pereira et al., 2017; Pirzgalska et al., 2017) demonstrates that
peripheral NE regulates adiposity levels independent of FI or ex-
ercise. As such, we hypothesized that PEGyAMPH treatment
could promote long-term anti-obesity results, regardless of
excessive caloric intake. To investigate this, we exposed adult
C57BL/6 male mice to HFD and treatment with either AMPH or
PEGyAMPH (120 mmol/kg of BW for both drugs or control
PBS, daily i.p. injections). As demonstrated before, AMPH pro-
tects mice from DIO (Figures 5A and 5B), while PEGyAMPH’s
sympathofacilitator activity is indeed sufficient to protect BW in
a dose-dependent manner (Figure S3G). Notably, when adminis-
trated in equimolar dose, treatment with PEGyAMPH showed
Figure 3. PEGyAMPH Facilitates SNS Activation via ADRB2 Signaling
(A) Representative traces of changes in membrane potential and AP evoked under current-clampmode in Vehicle, AMPH and PEGyAMPH-treated SCG neurons.
(B) Maximum AP firing frequency.
(C) Sequence of representative pseudocolor images of [Ca2+]i changes after stimulation with ACh.
(D) Representative ACh-induced [Ca2+]i response tracings in Vehicle, AMPH and PEGyAMPH-treated GCaMP3
+ neurons (left), and Amplitude of ACh-induced
[Ca2+]i transients (right). (n = 3-4; statistics done using one-way ANOVA followed by Bonferroni correction).
(E) Increase in NE content of iWAT (left) and liver (right) of C57BL/6mice post-treatment with PEGyAMPH (60, 120, or 240 mmol/kg of BW, i.p. injections). (n = 8–12;
statistics done using unpaired Student’s t test, with Holm-Sidak correction method).
(legend continued on next page)
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that of its unmodified counterpart (Figures 5A and 5B).
Moreover, both therapies also improved peripheral insulin
sensitivity, as blood glucose levels did not differ between all
groups (Figure S5A), but insulin was significantly lower in the
treated groups compared with those of the PBS controls (Fig-
ure S5B). Given that the SNS is reported not only to control insu-
lin sensitivity but also its secretion (Morton et al., 2017; Nono-
gaki, 2000; Ruud et al., 2017), we quantified NE content in the
pancreas and observed that only AMPH increased SNS tone in
this tissue (Figure S5C). Thus, PEGyAMPH treatment prevents
the development of hyperinsulinemia and improves glucose ho-
meostasis by increasing peripheral insulin sensitivity without
suppressing secretion. Analysis of liver gene expression re-
vealed that both treated groups had a 2-fold elevation of phos-
phoenolpyruvate carboxykinase (PEPCK) expression (Fig-
ure S5D), which is a main integrator of energy metabolism
(Burgess et al., 2007; Petersen et al., 2017; She et al., 2000).
Of note, the higher insulin sensitivity found in treated animals
during the fed-state was not associated with major differences
in glucose levels during an i.p. glucose tolerance test (GTT) (Fig-
ures S5E and S5G). Yet, the PEGyAMPH-treated group revealed
a trend toward higher peripheral glucose uptake during an insulin
tolerance test (ITT) (Figures S5F and S5H). Combined, these re-
sults indicate that long-term treatment with PEGyAMPHprotects
mice from DIO and improves glucose homeostasis during HFD
exposure.
As expected, PEGyAMPH-treated mice did not decrease their
FI (Figure 5C) or increase LA (Figures 5D and S5H) upon chronic
treatment. Nonetheless, indirect calorimetry revealed that, under
HFD feeding, this group had significantly higher energy expendi-
ture (EE) compared with the PBS controls (Figures 5E and S5G),
despite having similar behavior. We then analyzed the effects of
PEGyAMPH treatment on dietary lipid absorption and found that
it did not alter the total 24-h fecal output or its lipid content (Fig-
ure 5F). Plasma TGs levels of PEGyAMPH-treated mice were
also unchanged relative to controls (Figure 5G); thus, we can
conclude that PEGyAMPH promotes leanness by overriding
caloric intake. Finally, to test the efficacy of the treatments for
weight loss of already-obese animals, we also treated C57BL/6
mice previously exposed for minimum of 3 months to HFD,
with either AMPH or PEGyAMPH (120 mmol/kg of BW, i.p.) and
found that both drugs caused significant weight loss (>10%) af-
ter just 3 weeks of daily injections (Figures 5H and 5I).
Altogether, our results indicate that treatment with PE-
GyAMPH during HFD exposure overrides FI by increasing EE
and adrenergic-stimulated metabolic pathways.
PEGyAMPHProtects fromObesity by Elevating Lipolysis
and Lipid Utilization
As mentioned above, we found that PEGyAMPH’s anti-obesity
action is dose dependent as are its sympathofacillitor proper-(F) 3D structure of ADRB2 in complex with AMPH and PEGyAMPH. Left: Minim
ADRB2-PEGyAMPH complex, both showing the most relevant interactions betwe
atoms of the residues of this receptor that are interacting with the ligands are in
(G) Representative ACh-induced [Ca2+]i response (left), and Amplitude of ACh-ind
with PEGyAMPH, in the absence or presence of butoxamine (BUT) (right). (n = 3
*,#p < 0.05; *PBS versus PEGyAMPH; #PEGyAMPH versus PEGyAMPH+BUT. D
1126 Cell Metabolism 31, 1120–1135, June 2, 2020ties (Figures 3E and S3G, respectively). Thus, to dissect its
metabolic effects, we started by analyzing adipose SNS tone
after 10 weeks of HFD exposure and treatment. Surprisingly,
the PEGyAMPH-treated group exhibited a much greater NE
content in iWAT compared not only to the control group but
also to that of AMPH-treated animals (Figure 6A). This was
also associated with the presence of higher levels of lipolytic
markers in circulation, namely, free fatty acids (FFA) and glyc-
erol (Figures 6B and 6C), highlighting the potential of PE-
GyAMPH for chronic treatment. We observed a marked reduc-
tion in iWAT adipocyte size (Figures 6D and 6E) in both treated
groups relative to the same depot in PBS-treated animals.
Next, we probed changes of gene expression in several meta-
bolic tissues. PEGyAMPH induced an almost 3-fold upregula-
tion in b3-adrenoceptor (ADRB3) expression in iWAT, but not
in BAT (Figures 6F and 6G). This was accompanied by a
doubling of adipose triglyceride lipase (AtgL), while hormone-
sensitive lipase (HSL) showed increased expression in both
iWAT and BAT (Figures 6F and 6G). Combined with the upregu-
lation of adipose lipolysis, SNS tone was also found to be
elevated in liver and skeletal muscle (Figures S6A and S6D,
respectively) after treatment with PEGyAMPH, which suggests
higher metabolic performance, i.e., higher utilization of lipid
stores (Geerling et al., 2014; Nonogaki, 2000). In line with
this, we found decreased TG content accompanied by an in-
crease of glycogen (Figures S6B and S6C) in the livers of PE-
GyAMPH-treated mice. By performing oil red O (ORO) staining
and quantification (Figures 6H and 6I), we confirmed a marked
reduction in hepatic steatosis. In the skeletal muscle, PE-
GyAMPH caused a similar reduction of TG levels while preser-
ving glycogen stores (Figures S6E and S6F). Quantification of
gene expression in both liver and muscle confirmed alterations
of lipid metabolism in these tissues (Figures S6G and S6H).
Hence, PEGyAMPH’s protection against DIO seems to be
associatedwith a general elevation of peripheral lipid breakdown
and utilization, highlighting the SNS as a major regulator of
adiposity during excessive caloric intake.
PEGyAMPH Protects from Obesity by Elevating
Thermogenesis and Heat Dissipation via ADRB2
Activation of thermogenesis is also controlled by the SNS and can
act as an energy sink, promoting resistance to obesity (Rothwell
and Stock, 1979). Nonetheless, the rapid increase in EE observed
upon AMPH administration could be a result of increased LA, and
thus the contribution of its thermogenic activity to the elevation of
metabolic rate and BW management is still debated (Arch and
Trayhurn, 2013). To assess the thermogenic effect of each drug,
we used infrared thermography to analyze BAT temperature. After
PEGyAMPH treatment, therewas anelevation inBAT temperature
similar to that evoked by AMPH (Figures 7A and 7B). Accordingly,
we also found that both amphetamines caused a 15-fold upregu-
lation of the primary BAT thermogenic marker, uncoupling proteinized structure for ADRB2-AMPH complex, and Right: Minimized structure for
en ligand and receptor. ADBR2 is represented as white ribbons and the carbon
yellow. The carbon atoms of the ligands are in green.
uced [Ca2+]i transients in GCaMP3
+ neurons after pharmacological treatment
–4; statistics done using one-way ANOVA followed by Bonferroni correction).
ata presented as mean ± SEM. See also Figure S3.
Figure 4. PEGyAMPH, Unlike AMPH, Does Not Affect Cardiovascular Function, Unless Delivered Centrally
(A) Mean blood pressure (MBP).
(B) Systolic blood pressure (SBP) and diastolic blood pressure (DBP).
(legend continued on next page)
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ure 7C). This was accompanied by an 8-fold increase in the
expression of glucose-transporter-type-4 isoform (GLUT4) (Fig-
ure S7A), which indicates higher glucose uptake by this organ be-
ing a marker of higher thermogenic activity (Lee et al., 2016),
possibly accounting for the increased insulin sensitivity compared
with the PBS-treated controls (Figure S5B). AlthoughUCP1 levels
were not changed in iWAT, all other thermogenic genes quantified
were upregulated (Figure S7B), and others have reported thermo-
genesis with invariant UCP1 (Granneman et al., 2003; Ikeda et al.,
2017, 2018). The combination of these results reveals a general
trend for elevated thermogenesis after PEGyAMPH treatment,
which underlies its protection against DIO.
Surprisingly, we also detected that only AMPH caused tran-
sient hyperthermia (Borbély et al., 1974), while PEGyAMPH-
treated mice remain normothermic (Figure 7D). This suggests
that, although both drugs act as sympathomimetics, they might
actually have different actions on peripheral vasculature and
heat dissipation (Blessing et al., 2016). To assess vasoconstric-
tion at the extremities, we probed the local temperature at the tail
base by thermography (Fischer et al., 2016; Warner et al., 2013),
and found that, despite the similar core temperature, PE-
GyAMPH-injected mice had significantly warmer tails relative
to those of the controls (Figures 7E and 7F). This indicates
that, unlike AMPH, PEGyAMPH’s sympathomimetic activity in-
creases thermogenesis without causing vasoconstriction,
emphasizing thermoregulation as a relevant component of
adiposity control (Jéquier et al., 1974; Kasza et al., 2019; Warner
et al., 2013). Given that PEGyAMPH-treated mice rely on activa-
tion of thermogenesis to remain lean, we tested the effect of the
drug at thermoneutrality. As expected, PEGyAMPH anti-obesity
potency is decreased in this environmental setting, yet some
level of protection against DIO does remain (Figures 7G and
S7E). Furthermore, while thermogenesis is shown to be impor-
tant but not necessary for PEGyAMPH’s action, its facilitation
of heat dissipation seems to be driven by vasodilation, a process
well known to be controlled by ADRB2 (Chruscinski et al., 1999;
Ernande et al., 2016). Consistently, we discovered that the anti-
obesity effect of PEGyAMPH is abrogated by selective ADRB2
antagonism (BUT, Figures 7H and 7I), further validating the
importance of this pathway for PEGyAMPH’s metabolic effects.
Altogether, these results confirm that PEGyAMPH is a periph-
eral sympathofacilitator anti-obesity drug that activates a whole-
body energy sink by coupling thermogenesis to heat dissipation,
without inducing behavioral changes or cardiotoxicity.
DISCUSSION
The primary mechanism of action that underlies the anti-
obesity effect of AMPH-based drugs, such as FDA-approved(C) Heart rate of C57BL/6 mice, recorded post-injection with PBS, AMPH, or PEG
Pressure Recording (VPR) tail-cuff system.
(D–G) Measurements taken post-i.c.v. injection of PBS, AMPH, or PEGyAMPH (6
(D) Change in heart rate recorded using a CollarClip Sensor (CC-Sensor) for puls
(E) 24-h FI of i.c.v.-injected mice.
(F) Total distance traveled in 10 min.
(G) Representative trackings post-i.c.v. (n = 8–12; statistics done using unpaired
*,#,dp < 0.05; *PBS versus PEGyAMPH; #PBS versus AMPH; dPEGyAMPH versus
1128 Cell Metabolism 31, 1120–1135, June 2, 2020phentermine, is based on an effect in the brain that conveys
pronounced behavioral effects: anorexia and hyperkinesia.
Phentermine is a centrally acting anorexigenic drug that was
developed as a less addictive option to other AMPH forms.
However, studies in rodents have suggested that the anti-
obesity effects of AMPHs and other anorexigenic drugs are
partly, or even entirely, a result of non-behavioral factors
(Arch, 1981; Herling et al., 2008). Although anorexia unques-
tionably reduces BW, our results indicate that this effect de-
pends on an intact sympathetic axis (Pereira et al., 2017).
And as ADRB3 was described to be the main receptor medi-
ating adrenergic-stimulated lipolysis in rodent adipocytes
(Bloom et al., 1992; Guerra et al., 1998; Himms-Hagen et al.,
1994; Susulic et al., 1995; Xiao et al., 2015), direct sympatho-
mimetic agents, such as the ADRB3 agonist CL-316,243, were
once regarded as potential anti-obesity therapies. However,
as human lipolysis is mainly mediated by the other b-adrenor-
eceptors, ADRB3 agonists failed as anti-obesity therapies
(Arch, 2011; Lafontan and Berlan, 1993; Ursino et al., 2009).
Direct thermogenic drugs, such as compound 2,4-dinitro-
phenol, a mitochondrial uncoupler, were very effective anti-
obesity treatments through converting energy to heat, but
they also cause substantial side effects, including life-threat-
ening hyperthermia (Harper et al., 2001). The historical failure
of post-synaptic targeting in adipose tissue is suggestive of an
orchestrated multi-pathway and multi-organ program that is
pre-synaptically controlled by the SNS (Bartness et al.,
2014; Mahú and Domingos, 2017; Zeng et al., 2015). Thus,
we reasoned that a pre-synaptic facilitation of sympathetic
output would have a more potent effect, as SNS circuits
would simultaneously activate multiple pathways, not only in
WAT, but also in BAT and other metabolically relevant organs.
Indirect sympathomimetics, such as phentermine, demon-
strated higher anti-obesity efficacy relative to the direct class
but have prohibitive cardio-excitatory effects. However,
whether this side effect is mediated via the brain or periphery
had never been experimentally tested, and we addressed that
here by performing i.c.v. injections of AMPH and confirming
the central control of the cardiovascular effects. As such, we
reasoned and demonstrated that an exclusively peripheral
sympathofacilitator, PEGyAMPH, which does not enter the
brain, could be devoid of cardiovascular side effects. PE-
GyAMPH reduces obesity with a size effect comparable to
that of AMPH, yet with a distinct mechanism in that it spares
effects relating to brain action, such as anorexia, hyperkine-
sia, and tachycardia.
Engagement of ADRB2 seems to be required for the sympa-
thofacilitatory and weight-loss effects of this drug. And elevation
of SNS tone, both to WAT and BAT, activates lipolysis and ther-
mogenesis (Bartness et al., 2014; Contreras et al., 2017;yAMPH (120 mmol/kg of BW for both drugs, i.p.) using a non-invasive Volume
0 nmol, bolus, per animal).
e oximetry.
Student’s t test, with Holm-Sidak correction method).
AMPH. Data presented as mean ± SEM. See also Figure S4.
Figure 5. PEGyAMPH Protects Mice from DIO and Increases EE without Affecting Food Intake
(A and B) BW (A) and DBW (B) of C57BL/6 mice during HFD exposure and treatment with PBS, AMPH, or PEGyAMPH (120 mmol/kg of BW for both drugs,
daily i.p.).
(legend continued on next page)
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2015). Simultaneously, ADRB2 agonism is well known to lead
to smooth muscle relaxation and vasodilation, which bode well
to mediate the cardioprotective actions of PEGyAMPH, as well
as its effect on thermal dissipation. Consistently, others have
shown that the ADRB2-selective agonist salbutamol, increases
BAT vasodilation and tissue perfusion, activating thermogenesis
without directly targeting brown adipocytes (Ernande et al.,
2016). The authors of this report did not assess changes in pe-
ripheral vasculature, and we did not probe BAT perfusion, but
it is quite possible that PEGyAMPH might also increase blood
flow to this tissue, further boosting thermogenesis. Moreover,
although the relationship between peripheral vascular tone and
cardiac function is undebatable (Delong and Sharma, 2019),
the effect of blood flow on heat dissipation and its connection
to metabolic regulation has only recently began to be appreci-
ated as an important component of adiposity control. In fact,
compensatory thermoregulation seems to drive hypermetabolic
phenotypes in animals with genetic manipulations that facilitate
heat dissipation (Kasza et al., 2019; Reimúndez et al., 2018;
Warner et al., 2013).
Our results put forward the idea that coupling increases ther-
mogenesis with peripheral heat dissipation, constitutes a sink for
EE without causing hyperthermia, and that AMPH-like com-
pounds, such as phentermine or ADRB2 agonists, which are
not indicated for long-term systemic use due to serious side ef-
fects, could be reformulated to become brain impermeable.
Overall, our results are a proof-of-principle that peripheral sym-
pathofacilitators could be a new generation of anti-obesity com-
pounds that circumvent difficulties caused by BBB permeability
and avoid brain-related side effects, including those relating to
cardiovascular function.
Limitations of Study
Considering the underappreciated promiscuity of several
FDA-approved drugs, which can bind, on average, to 12 or
more distinct targets (Reker et al., 2014a, 2014b; Rodrigues
et al., 2016), we cannot exclude that PEGyAMPH, or even
AMPH, binds a plethora of targets not covered in this study.
Notwithstanding this limitation, PEGyAMPH’s effect on weight
requires a functional ADRB2, and its cardiac side effects
require access to the brain. Systemically administered
ADRB2 agonists have been illicitly used for weight manage-
ment and their cardiac side effects have long been a public
health and safety concern (Salpeter, 2004; Spiller et al.,
2013). Whether brain-sparing agonists phenocopy the anti-
obesity and cardioprotective effects of PEGyAMPH will have
to be experimentally tested—the loss of function of ADRB2
in this study is limited to demonstrating necessity and does
not predict the outcome of a gain of function of ADRB2 based
on peripherally restricted agonists.(C) Average FI.(D) Daily LA, quantified in beam-break counts.
(E) EE, normalized to total BW.
(F) Daily fecal output (left) and fecal TGs content (right).
(G) Plasma TGs levels.
(H and I) BW (H) and DBW (I) of DIO mice during treatment. (n = 8–15; statistics
unpaired Student’s t tests, with Holm-Sidak correction method, for the other ass
*,#,dp < 0.05; *PBS versus PEGyAMPH; #PBS versus AMPH; dPEGyAMPH versus
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Deposited Data
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Other
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Calorimetric System LabMaster TSE Systems N/A
Toshiba Camileo HD Toshiba Cat#PA4083E-1CAM
ABI QuantStudio 7 Applied Biosystems Cat#4485701
Axiovert 135 TV Zeiss N/A
Toohey Spritzer pressure system
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Toohey Company N/A
CoolSNAPfx CCD Camera Photometrics N/A
Axopatch 200B Microelectrode Amplifier Axon Instruments N/A
FTICR mass spectrometer - Bruker
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Bruker N/A
Eppendorf Concentrator Plus system Eppendorf Cat#5305000100
Shimadzu HPLC System Shimadzu UK Limited N/A
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Micro-Osmotic PUMPs Alzet Cat#1004
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Lead Contact
Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Ana I. Domingos (ana.
domingos@dpag.ox.ac.uk). All data that support the findings herein presented are available from the corresponding authors upon
reasonable request.
Materials Availability
We developed a PEGylated version of amphetamine, for which the reaction protocol is described in the methods section. The modi-
fied drug can be produced and purchased at WuXi AppTech upon request for research purposes only.
Data and Code Availability
The results generated using PatchDock web server are available at: [http://bioinfo3d.cs.tau.ac.il/PatchDock/runs/6H7J_receptorH.
pdb_PEGyAMPH.pdb_19_56_7_10_2_120/; http://bioinfo3d.cs.tau.ac.il/PatchDock/runs/6H7J_receptorH.pdb_AMPH.pdb_50_0_
8_10_2_120/]. The results generated using FireDock web server are available at: [http://bioinfo3d.cs.tau.ac.il/FireDock/runs/
6H7J_receptorH.pdb_PEGyAMPH.pdb_28_57_7_10_2_120/; http://bioinfo3d.cs.tau.ac.il/FireDock/runs/6H7J_receptorH.pdb_
AMPH.pdb_27_1_8_10_2_120/]. Original data related to the coordinates of the Minimized Complexes and input files have
been deposited to Mendeley Data [https://doi.org/10.17632/cxx6gy2rjx.2] and are accessible in the dropbox link found in the
Key Resources Table.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice and Housing Conditions
Mice were housed at controlled temperature and humidity, under a 12 h light/dark cycle. Food and water were supplied ad libitum, un-
lessmentioned otherwise. All animal protocols were approved by the Instituto Gulbenkian deCiência ethical committee and the ‘‘Órgão
Responsável pelo Bem-estar dos Animais’’ (ORBEA). These were consequently licensed by the Direccão Geral de Alimentação e Vet-
erinária (DGAV - Project ID 15010/14/006). All experimental procedures follow the Portuguese (Portaria n 1005/92, Decreto-Lei n 113/
2013) and European (Directive 2010/63/EU) legislations, concerning housing, husbandry and animal welfare. C57BL/6J mice were ob-
tained from Charles River and bread in the Mice Production Facility at the IGC. TH-cre (Jax, #008601), CAG-LSL-GCaMP3 (Jax,
#014538), LSL-DTR (Jax, #007900), mice were purchased from Jackson Laboratory, and bred inhouse to produce homozygous TH-
cre; CAG-LSL-GCaMP3 and TH-cre; LSL-DTR mice. LSL-DTR mice were used as controls for the sympathectomization studies.
PEGyDT-Mediated REGIONAL SYMPATHECTOMY
For detailed characterization refer to Pereira et al., 2017. Briefly, reconstitute Diphtheria Toxin (DT - Sigma) and MS(PEG)4 Methyl-
PEG-NHS-Ester (Life Technologies) according to manufacturer instructions. For each 1 g of DT add 0.423 mg of PEG and incubate
the reaction for 4 h at RT under agitation using a shaker to produce the stock solution of PEGylated DT (PEGyDT). 7-8 weeks old TH-
cre; LSL-DTR male mice were used for genetic-sympathectomy experiments and aged-matched LSL-DTR were used as controls.
PEGyDTwas administered once a day for 8 consecutive days (25 ng/g of BW, i.p. injections, diluted in PBS). All following experiments
were performed at least 24 h after the last injection.
High-Fat Diet Challenge and Chronic Treatments
All mice used for DIO challenges and follow-upmetabolic analysis weremales. When C57BL/6 male mice reached 8 weeks of age, or
1 day after sympathectomy protocol was performed in both TH-cre; LSL-DTR and respective controls LSL-DTR, normal diet was
replaced with high fat diet (Ssniff Spezialdi€aten, D12492) concomitantly with treatment of either AMPH or PEGyAMPH (dose:
120 mmol/kg of BW for both drugs diluted in PBS, daily i.p. injections). Length of exposure to HFD and treatment is indicated in figure
legends. Butoxamine was delivered via micro-osmotic pumps (dose:16 mmol/kg/day), implanted intraperitoneally 1 week before
treatment with PEGyAMPH (Alzet).
SCG Neurons Culture and Treatments
Primary cultures of SCG neurons were performed from postnatal day 30 C57BL/6 or TH-cre; CAG-LSL-GCaMP3 mice (male and
female). After decapitation, both SCG of each animal were removed and cleaned of all visible adipose tissue and surrounding
connective tissue before transfer to Dulbecco’s Modified Eagle Medium (Biowest). Then, SCG were treated enzymatically in two
steps to yield single neurons in accordance to the method described by Motagally and collaborators (Motagally et al., 2009), with
some modifications. First, SCG were subjected to enzymatic dissociation in 2.5 mg/mL collagenase solution (Sigma-Aldrich) in
Hank’s Balanced Salt Solution (HBSS) without calcium and magnesium (Gibco, Life Technologies) at 37C with agitation, followed
by 0.25% trypsin solution (Biowest) in PBS at 37Cwith agitation. SCGwas thenmechanically dissociated into a suspension of single
cells. The isolated sympathetic neurons were plated, 2500 cells per coverslip (6 mm) coated with poly-d-lysine (Sigma) and growth
factor-reduced Matrigel (BD Biosciences) and cultured in Neurobasal medium (Gibco) supplemented with 2% B-27 (Gibco), 10%e3 Cell Metabolism 31, 1120–1135.e1–e7, June 2, 2020
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deoxyuridine (Sigma-Aldrich). Cells were kept in culture for 6 days in vitro at 37Cwith 5%CO2 conditioned atmosphere to obtain an
enriched culture of sympathetic neurons. Beforemeasurements, neuronswere incubatedwith 15 mMAMPHor 15 mMPEGyAMPH for
24 h at 37C with 5% CO2 conditioned atmosphere. Butoxamine (Santa-Cruz Biotechnology) was add at a concentration of 10mM,
30min prior to the calcium-imaging experiments.
METHOD DETAILS
PEGylation of Amphetamine (PEGyAMPH Synthesis)
Inspired by Yang et al. (2009). Briefly, in a round-bottom flask (R)-1-phenylprop-2-ylamine hydrochloride salt (103 mg, 0.6 mmol, 2
equiv., Asiba Pharmatec.) was placed under inert atmosphere. A solution of methyl-PEG-NHS-ester reagent (1.1 mL, 100 mg,
0.39 mmol, 1 equiv., Thermo Scientific) in DMSO was then added, followed by the addition of diisopropylethylamine (DIPEA,
105 mL, 0.6 mmol, 2 eq, Sigma-Aldrich). The reaction was stirred at room temperature for 46 h, after which a multiple extraction
with water/ethyl acetate was performed to remove the product from DMSO. Then preparative chromatography (5% EtOAc in
MeOH, v/v) was performed to isolate compound PEGyAMPH in 98% yield (0.1 g). Characterization: 1H NMR (300 MHz, CDCl3)
d 7.25 – 7.11 (m, 5H), 6.53 – 6.26 (m, 1H), 4.19 (p, J = 6.8 Hz, 1H), 3.63 – 3.47 (m, 14H), 3.32 (s, 3H), 2.79 (dd, J = 13.5, 6.1 Hz,
1H), 2.65 (dd, J = 13.5, 7.1 Hz, 1H), 2.37 (t, J = 6.4 Hz, 2H), 1.06 (d, J = 6.6 Hz, 3H) ppm. 13C NMR (75 MHz, CDCl3) d 170.92,
138.38, 129.55, 128.36, 126.40, 72.01, 70.70, 70.60, 70.46, 70.34, 67.43, 59.11, 46.02, 42.60, 37.21 ppm. HRMS: [M+H]+calc =
354.22750; [M+H]+real = 354.22783 (error –0.9 ppm). Scale-up of the reaction for the chronic in vivo treatments was reproduced
by Wuxi AppTec.
Intracerebroventricular Treatments
Intracerebroventricular (i.c.v.) cannulae were stereotaxically implanted under a mix of inhaled isoflurane and oxygen, using the
following coordinates 1.5 mm lateral to bregma, 0.6 mm posterior, 4.0 mm deep. Mice equipped with i.c.v. cannulae were given
7 days to recover before injections and measurements. A bolus i.c.v. injection of AMPH or PEGyAMPH (60 nmol, diluted in 5 mL
of PBS), or of PBS as control was acutely administrated for behavioral and cardiorespiratory measurements as described below.
Non-invasive Cardiovascular Measurements
Blood Pressure and Heart Rate weremeasured from awake restrained animals using a Volume Pressure Recording (VPR) sensor and
tail-cuff system (CODA, Kent Scientific Corporation). To prevent stress-related effects, mice were trained for a minimum of 3 days
before measurements. At least 15 accurate measurements per animal were used for analysis of diastolic, mean and systolic pressure
and at least 8 for analysis of the heart rate. Baseline was recorded just before injection, and the effect of the drugs was measured 15-
30 min post injection with PBS, AMPH or PEGyAMPH (dose: 120 mmol/kg of BW for both drugs, daily i.p. injections).
Infrared Pulse Oximetry
Thedaybeforemeasurements thehairaround theneckofeachmousewas removedusingVeetcream(Unilever). 24-48hpost-depilation,
thecardiopulmonary statusof eachmousewasanalyzedbyMouseOxPlus (Starr LifeSciencesCorp) in accordancewithmanufacturer’s
instructions.Eachmousewasverybrieflyanaesthetisedusing5%isoflurane to facilitateplacementofaCollarClipSensor, andallowed to
acclimatize to the anesthesiawith 1-2% isoflurane for 5min. This timewindowwas sufficient for animals to recover normal activities and
physiological readings.Measurementswere then recorded for 5-10min at baseline and then for another 10-15min after injections (i.p. of
PEGyAMPHand AMPH, dose: 120 mmol/kg of BW for both drugs; or i.c.v. of PBS and AMPH, dose: 60nmol, bolus per animal). The time
points described were used to collect representative, error-free data due to the motion artefact (DeMeulenaere, 2007).
Locomotion Assays
After 3 weeks of HFD exposure and treatment, mice were acclimated to tracking cages for 1 week before starting the 72h locomotion
measurements by using a high throughput tracking system (LabMaster, TSE Systems). Animals were also filmed for 20-30min, with a
Toshiba Camileo HD camera 1 h post-injection inside their normal housing cage, for assessment of total distance travelled. Footage-
records were filtered by using video editor Avidemux (Avidemux 2.7.1) and 10-15min distance computations were quantified with the
TrackMate tracking plugin from Fiji (Fiji; Wisconsin-Madinson).
Calorimetry Assays
Animals were analysed for Energy Expenditure (EE) using a calorimetric system (LabMaster; TSE Systems). Animals were placed in a
temperature-controlled (24C) box through which air was pumped. After calibrating the system with the reference gases (20.9% O2,
0.05%CO2 and 79.05%N2), themetabolic rate wasmeasured for 2-3 days, and EEwas recorded every 30min. Animals were placed
for adaptation for 1 week before starting the measurements. Normalized EE was calculated as described in Tschöp et al. (2011) and
the distribution curves were obtained using the CalR Web-based tool (Mina et al., 2018).Cell Metabolism 31, 1120–1135.e1–e7, June 2, 2020 e4
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For the intraperitoneal Glucose Tolerance Test (GTT),micewere injectedwith PBS, AMPHor PEGyAMPHand then fasted for 6 h, before
being given 2 g glucose/kg of BW, i.p. Blood was drawn from the tail vein and glucose levels weremeasured using a glucometer (Accu-
Check System, Roche) at 0, 15, 30, 60, 90, and 120 min after glucose administration. For the Insulin Tolerance Test (ITT), mice were
injected with PBS, AMPH or PEGyAMPH and then fasted for 2 h, before being given (i.p.) 0.9U/kg of BW, i.p., of recombinant human
insulin (Sigma), blood glucose levels were measured at 0, 15, 30, 60, 90, 120, 150 and 180 min after insulin administration.
Thermoregulation Analysis
All measurements were done in ad libitum fed mice 2 h post-injections with PBS, AMPH or PEGyAMPH. Rectal temperature was
measured with an electronic thermometer (Physitemp). BAT and Tail thermographic pictures were taken with a Compact-
Infrared-Thermal-Imaging-Camera (FLIR) and FLIR-Tools-Software (FLIR), to quantify local temperature (Martı́nez-Sánchez
et al., 2017).
Blood and Plasma Analysis
Blood was collected from the tail vein of HFD fed mice 2 h post-injections with PBS, AMPH or PEGyAMPH, without access to food.
Blood glucose was measured with a glucometer (Accu-Check, Roche). Analysis of Insulin, Triglycerides, Glycerol and FFA levels in
plasma was performed by using Mouse Ultrasensitive Insulin ELISA (Alpco), Triglyceride Quantification Kit (Abcam), Free Glycerol
Reagent (Sigma) and Glycerol Standard Solution (Sigma), and Free Fatty Acid Quantification Kit (Sigma), respectively according
to manufacturer’s instructions.
Tissue NE Measurements (ELISA)
To assess peripheral NE content in tissues, mice were sacrificed in ad libitum conditions 2 h post injection with PBS, AMPH or PE-
GyAMPH. NE levels were determined with a NE ELISA kit (Labor Diagnostika Nord GmbH). Tissues were homogenized and sonicated
in homogenization buffer (1 M HCl, 1 mM EDTA, 4 mM sodium metabisulfite), and cellular debris was pelleted by centrifugation at
20,000 g for 10 min at 4C). All tissue samples were normalized to total tissue protein concentration, measured with Protein Assay
Dye Reagent Concentrate (Bio-Rad), according to manufacturer’s instructions.
Fecal Output Assay
24 h fecal output was collected and weighed. The feces were washed with 1x PBS and total triglyceride content was extracted by
homogenization and boiling, for 2 cycles of 5 min, in 5%NP-40. Triglyceride content was measured using Triglyceride Quantification
Kit (Abcam), according to manufacturer’s instructions, and normalized to the weight of total fecal output.
Tissue Triglycerides Analysis
To assess gastrocnemius muscle and liver content in tissues, mice were sacrificed in ad libitum conditions 2 h post injection with
PBS, AMPH or PEGyAMPH. Triglyceride content was measured using Triglyceride Quantification Kit (Abcam), according to manu-
facturer’s instructions. Tissue samples were normalized to total tissue protein concentration, measured with Protein Assay Dye Re-
agent Concentrate (Bio-Rad), according to manufacturer’s instructions.
Quantitative PCR
For gene expression analysis mice were sacrificed in ad libitum conditions 2 h post injection with PBS, AMPH or PEGyAMPH, tissues
were collected and immediately frozen. RNA from SCG and BAT was extracted using RNeasy Plus Micro Kit (Qiagen) and from all
other tissues the RNA was extracted using PureLink RNA Mini Kit (Life Technologies) according to manufacturer’s instructions.
From total tissue RNA of all samples complementary DNA was reverse-transcribed by using SuperScript II (Invitrogen) and random
primers (Invitrogen). Quantitative PCRwas performedwith SYBRGreen (Invitrogen) in ABI QuantStudio 7 (Applied Biosystems). Glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) was used as housekeeping gene to normalize liver and gastrocnemius muscle
tissue samples. Acidic ribosomal phosphoprotein P0 (Arbp0) was used as housekeeping gene to normalize adipose tissues samples.
The list of primers used is shown in Table S1.
Histopathology Analyses
Mouse tissues were fixed in buffered formalin, and inclusion in paraffin was done according to standard technical procedures. His-
topathology studies were performed on formalin-fixed and paraffin-embedded sections of 3–6 mm thick for Haematoxylin and Eosin.
Tissues were analysed with a Leica DM LB2 microscope, and images captured with a Leica DFC 250 camera.
Intracellular Calcium-Imaging
For Ca2+ experiments, sympathetic neurons were obtained from TH-cre; CAG-LSL-GCaMP3mice. At 7 DIV, coverslips with sympa-
thetic neurons from GCaMP3+ mice were mounted on an inverted microscope with epifluorescent optics (Axiovert 135TV, Zeiss)
equipped with a xenon lamp (located at a Lambda DG-4, Sutter Instrument) and band-pass filter of 450-490 nm wavelengths.
Ca2+ measurements were performed at 37C, as reported in (Jacob et al., 2014). Throughout the experiments the Ach was applied
focally through a drug-filled micropipette placed under visual guidance over a single neuronal cell. Drug release was performed bye5 Cell Metabolism 31, 1120–1135.e1–e7, June 2, 2020
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physiological solution did not cause any measurable change in intracellular Ca2+ concentration. Images were obtained every 250 ms
by exciting the preparations at 450-490 nm and the emission wavelength was set to 510 nm. Neurons were imaged with a cooled
CCD camera (Photometrics CoolSNAP fx), processed and analysed by using the softwareMetaFluor (Molecular Devices). Ca2+ levels
were recorded at the cell body of neurons (manually defined over the cell profile) in the field of view and variations were estimated as
changes of the fluorescence signal over the baseline (DF/F0 = [(Fpost – Frest)/Frest]).
Electrophysiology
Whole cell patch-clamp recordings performed at 7 DIV in dissociated cultures of sympathetic neurons from C57BL/6 mice using an
upright microscope (Zeiss Axioskop 2FS) equipped with differential interference contrast optics by using a Zeiss AxioCam MRm
camera and a x40 IR-Achroplan objective. During recordings, cells were continuously superfused with artificial cerebrospinal fluid
containing (in mM: 124 NaCl, 3 KCl, 1.2 NaH2PO4, 25 NaHCO3, 2 CaCl2, 1 MgSO4 and 10 glucose), which was continuously gassed
with 95% O2/5% CO2. Recordings were performed at room temperature in current-clamp or voltage-clamp mode [holding potential
(Vh) = -60 mV] with an Axopatch 200B amplifier (Axon Instruments) (Félix-Oliveira et al., 2014). Briefly, patch pipettes with 4 to 7 MU
resistancewhen filledwith an internal solution [containing (inmM): 125 K-gluconate, 11 KCl, 0.1 CaCl2, 2MgCl2, 1 EGTA, 10HEPES, 2
MgATP, 0.3 NaGTP, and 10 phosphocreatine, pH 7.3, adjusted with 1 M NaOH, 280-290 mOsm] were used to record excitatory syn-
aptic currents and action potential activity. The junction potential was not compensated for, and offset potentials were nulled before
gigaseal formation. The resting membrane potential was measured immediately upon establishing whole cell configuration. Firing
patterns of sympathetic neurons were then immediately assessed in current-clamp mode by injection of 500 ms current pulses
(-25–275 pA in 12.5 or 25 pA increments) from an initial holding potential (Vh) of 70 mV. For each neuron, the threshold for action
potential generation was determined bymembrane potential at which phase plot slope reached 10mV/ms (Naundorf et al., 2005). For
each neuron, D depolarization for AP firing was calculated as the difference between the resting membrane potential and the
threshold for action potential generation.
Fourier-Transform Ion Cyclotron Resonance (FT-ICR) Mass Spectrometry
12 weeks old male C57BL/6 mice were injected i.p. and sacrificed 30 min post-injection with AMPH or PEGyAMPH (dose: 120 mmol/
kg of BW for both drugs). Brain samples were snap-frozen in liquid nitrogen before extraction procedures (Agudelo et al., 2014).
Whole brain samples were smashed and extracted using ice-cold 1 mM perchloric acid (500 mL per sample) and left extracting over-
night. After this time, the samples were centrifuged twice for 20 min at 5000 rpm, 4C. Supernatants were transferred to new vials,
frozen and freeze dried overnight each time, concentrated to 50 mL. Then, 25 mL of the remaining solutions were diluted in 75 mL of an
electrospray ionization solution (CH3CN:H2O, 3:1). The sampleswere then evaluated through direct injection by using a Fourier-trans-
form ion cyclotron resonance (FT-ICR) mass spectrometer (Bruker Apex Ultra, 7 Tesla actively shielded magnet).
Quantitative Liquid Chromatography with Mass Spectrometry Detection
8-12weeks old C57BL/6micewere injected i.p. and sacrificed 30min post-injection with AMPHor PEGyAMPH (dose: 120 mmol/kg of
BW for both drugs). Plasma and tissue samples were snap-frozen in liquid nitrogen upon collection and extraction procedures were
prepared by a protein crash method for the extraction and quantitative analysis of drug content. Briefly, around 100 mg of tissue
(brain and heart) were added to 100 mL of water inside a plastic screw-cap Eppendorf vial, followed by the addition of 100 mL of
the stable isotope amphetamine internal standard (Amphetamine-d11 at 100 nM in water). Then a 5 mm stainless steel ball bearing
was added to each sample. The samples were then homogenized using a Bioprep-24-1004 homogenizer (Allsheng) run at speed;
5 m/s, time; 30 seconds for 2 cycles. Then, 250 mL of acetone was added to each sample to precipitate any proteins in the solution.
The samples were thoroughly vortexed to ensure optimal analyte recovery (recovery was >75%). The samples were then centrifuged
(5 min at 20,000 g) to produce a clear supernatant separate from any solid particles. The supernatant was then transferred in to a
separate 2 mL amber glass auto-sampler vial (Agilent Technologies). The acetone solvent was then evaporated-off by concentrating
the sample on an Eppendorf Concentrator Plus system (Eppendorf) run for 20 minutes at 60 degree Celsius. The remaining sample
(200 mL) was then transferred into a 300 mL low-volume vial insert inside a 2 mL amber glass auto-sample vial ready for liquid chro-
matography with mass spectrometry detection (LC-MS). Full chromatographic separation of the analytes (AMPH and PEGyAMPH)
was achieved using Shimadzu HPLC System (Shimadzu UK Limited) with the injection of 5 mL onto a Acquity UPLC BEH C18 col-
umn; 1.7 mm, I.D. 2.1 mm X 50 mm (Waters), maintained at 40C. Mobile phase A was water with 0.1% formic acid. Mobile phase B
was acetonitrile with 0.1% formic acid. The flow was maintained at 500 mL per minute through the following gradient: 0.00 mi-
nutes_1% mobile phase B; 1.00 min, 1% mobile phase B; 2.00 min, 95% mobile phase B; 3.30 min, 95% mobile phase B;
3.40 min, 1% mobile phase B; 6.50 min, 1% mobile phase B. The sample injection needle was washed using acetonitrile with 0.1
% formic acid. The mass spectrometer used was the Exactive Orbitrap with a heated electrospray ionization source (Thermo Fisher
Scientific). Themass spectrometer was calibrated immediately before sample analysis using positive and negative ionization calibra-
tion solution (recommended by Thermo Fisher Scientific). Additionally, the heated electrospray ionization source tune files were opti-
mized for both AMPH and PEGyAMPH independently and applied to the mass spectrometry method by segmenting the MSmethod;
this produced the lowest limit of quantitation for each compound. AMPH segment 1 was run in positive mode from 0 to 2.9 minutes
with the mass spectrometer resolution set to 50,000 with a full-scan range of m/z 60 to 1200 Da. PEGyAMPH segment 2 was run in
positive mode from 2.9 to 5 minutes with the mass spectrometer resolution set to 50,000 with a full-scan range of m/z 60 to 1200 Da.Cell Metabolism 31, 1120–1135.e1–e7, June 2, 2020 e6
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NH3]+ at retention time 2.73 minutes; AMPH-d11: 147.18112 [M+H]+ and 130.1551 [M+H-NH3]+ at retention time 2.72 minutes; PE-
GyAMPH: 354.22750 [M+H]+ at retention time 3.12 minutes). The area under the curve of these high resolution extracted ion chro-
matograms (with a window of ± 8 ppm) were normalized to the internal standard (amphetamine-d11) to account for extraction and
instrument variations and then compared to a quantitative calibration line (lower limit of quantitation: 10 nM; upper limit of quantita-
tion: 1,000 nM, for both compounds). The calculated concentrations of the analytes were then divided by the amount of tissue used in
the extraction protocol to give the final results in nM per mg of tissue extracted (nM/mg).
Docking Calculations and Molecular Mechanics Minimizations
The X-ray structure reported for these receptors in complex with epinephrine (pdb ID: 6H7J and 4LDO, respectively - Ring et al. (2013)
was used as a 3Dmodel of the protein complex. The Docking calculations between the ligands and the receptor were performed with
PatchDock Server and FireDock (Schneidman-Duhovny et al., 2005). Molecular mechanics minimizations were then carried out on
the complexes using AMBER 18 package, (D. A. Case, I. Y. Ben-Shalom, S. R. Brozell, D. S. Cerutti, T. E. Cheatham, III, V. W. D.
Cruzeiro, T. A. Darden, R. E. Duke, D. Ghoreishi, M. K. Gilson, H. Gohlke, A. W. Goetz, D. Greene, R Harris, N. Homeyer, Y. Huang,S.
Izadi, A. Kovalenko, T. Kurtzman, T. S. Lee, S. LeGrand, P. Li, C. Lin, J. Liu, T. Luchko, R. Luo, D. J.Mermelstein, K. M. Merz, Y. Miao,
G. Monard, C. Nguyen, H. Nguyen, I. Omelyan, A. Onufriev, F. Pan, R. Qi, D. R. Roe, A. Roitberg, C. Sagui, S. Schott-Verdugo, J.
Shen, C. L. Simmerling, J. Smith, R. Salomon Ferrer, J. Swails, R. C. Walker, J. Wang, H. Wei, R. M. Wolf, X. Wu, L. Xiao, D. M.
York and P.A. Kollman (2018), AMBER 2018, University of California, San Francisco), which was implemented with ff14SB (Maier
et al., 2015) and GAFF (Wang et al., 2004) force fields. Parameters for the ligands (AMPH and PEGyAMPH) were generated with
the antechamber module of AMBER, using GAFF force field and with partial charges set to fit the electrostatic potential generated
with HF/6-31G(d) by RESP (Bayly et al., 1993). The charges were calculated according to the Merz-Singh-Kollman scheme using
Gaussian 16.(Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone,
V.; Petersson, G. A.; Nakatsuji, H; et al. Gaussian 16 rev. B.01, 2016, Wallingford, CT) The complexes were immersed in a water
box with a 10 Å buffer of TIP3P water molecules (Jorgensen et al., 1983) and neutralized by adding explicit counter ions. A two-stage
geometry optimization approach was performed with a total of 5000 minimization steps and using the default settings of AMBER 18.
The first stageminimizes only the positions of solvent molecules and ions, and the second stage is an unrestrainedminimization of all
the atoms in the system.
QUANTIFICATION AND STATISTICAL ANALYSIS
The number of animals used in each experimental setting (n) and the analysis performed are specified in the figure legends. The sta-
tistical analyses were performed with GraphPad Prism software (San Diego, CA) using unpaired Student’s t-test (two-tailed) or one-
way ANOVA for single comparisons, with one group indicated as the control, and two-way ANOVA when comparing changes over
time. p< 0.05 was considered statistically significant. Data are represented as mean ± S.E.M. Data displayed normal variance.e7 Cell Metabolism 31, 1120–1135.e1–e7, June 2, 2020
